Scynexis (SCYX) Total Current Liabilities (2013 - 2026)
Scynexis' (SCYX) quarterly Total Current Liabilities came in at $5.8 million in Q2 2026, down 46.38% on a YoY basis from $10.9 million in Q2 2025, and down 63.36% quarter-over-quarter from $15.9 million in Q1 2026.
Analysis
Scynexis (SCYX) Total Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Total Current Liabilities for 14 consecutive years, with $5.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Current Liabilities fell 46.38% year-over-year to $5.8 million; the trailing twelve-month figure through Jun 2026 stood at $5.8 million (down 46.38% YoY), and the FY2025 full-year result was $5.7 million, down 76.21% from the prior year.
- Total Current Liabilities declined to $5.8 million in Q2 2026 per SCYX's latest filing, from $15.9 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $45.6 million in Q1 2023 and bottomed at $5.7 million in Q4 2025.
- Historically, Total Current Liabilities has averaged $17.4 million across 5 years, with a median of $16.1 million in 2022.
- The sharpest annual moves came in 2023 and 2025: Total Current Liabilities soared 252.63% in 2023, then plunged 76.21% in 2025.
- Over 5 years, Total Current Liabilities stood at $17.6 million in 2022, then retreated by 7.46% to $16.3 million in 2023, then soared by 47.82% to $24.1 million in 2024, then slumped by 76.21% to $5.7 million in 2025, then increased by 1.59% to $5.8 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $5.8 million, $15.9 million, and $5.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 25.50 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.02 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 3.94 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 5.53 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.58 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 2.53 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 3.92 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 283.60 Mn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 5.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.83 Mn |
| Mar 31, 2026 | 15.90 Mn |
| Dec 31, 2025 | 5.73 Mn |
| Sep 30, 2025 | 8.47 Mn |
| Jun 30, 2025 | 10.86 Mn |
| Mar 31, 2025 | 8.96 Mn |
| Dec 31, 2024 | 24.10 Mn |
| Sep 30, 2024 | 25.72 Mn |
| Jun 30, 2024 | 25.23 Mn |
| Mar 31, 2024 | 27.35 Mn |
| Dec 31, 2023 | 16.30 Mn |
| Sep 30, 2023 | 16.79 Mn |
| Jun 30, 2023 | 16.16 Mn |
| Mar 31, 2023 | 45.64 Mn |
| Dec 31, 2022 | 17.62 Mn |
| Sep 30, 2022 | 14.26 Mn |
| Jun 30, 2022 | 16.01 Mn |
| Mar 31, 2022 | 12.94 Mn |
| Dec 31, 2021 | 13.62 Mn |
| Sep 30, 2021 | 13.22 Mn |